ERBB2 and cancer: A phase I clinical trial including intracavitary liposome‐complexed E1A gene in breast and ovarian cancer showed decreased HER‐2 protein levels, enhanced E1A expression in cancer and normal cells, reduced pleural or peritoneal cancer cells, and increased apoptosis.248